Phase I study of olaratumab in Japanese patients with advanced solid tumors.
Bottom Line: The most common olaratumab-related treatment-emergent adverse events (TEAEs) were proteinuria (25.0%) and elevated aspartate transaminase (12.5%).One patient (cohort 2) had two olaratumab-related Grade 3 TEAEs (increased aspartate aminotransferase and tumor hemorrhage); otherwise, olaratumab-related TEAEs were Grade 1/2.Seven patients (43.8%) had a best response of stable disease.
Affiliation: National Cancer Center Hospital East, Kashiwa, Chiba, Japan.Show MeSH
Related in: MedlinePlus
Mentions: Of the seven patients with a best response of SD, two patients in cohort 3 experienced disease stabilization >4 months; these patients had hypopharyngeal cancer (4.2 months) and leiomyosarcoma of inferior vena cava origin (5.6 months). The others experienced disease stabilization that lasted approximately 2.8 months each. Figure 1 shows time on treatment for each patient.
Affiliation: National Cancer Center Hospital East, Kashiwa, Chiba, Japan.